{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:18:58Z","timestamp":1788430738885,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Low-density lipoprotein cholesterol (LDL-C) is a\u00a0causal risk factor for atherosclerotic cardiovascular disease (ASCVD). ESC\/EAS guidelines recommend reducing LDL-C\u202f&lt;\u20091.4\u202fmmol\/L and &gt;\u202f50% from baseline in patients with myocardial infarction. \u201cJena auf Ziel\u201d (JaZ) is a\u00a0prospective cohort study in which early combination therapy with atorvastatin 80\u202fmg and ezetimibe 10\u202fmg was initiated on admission in patients with ST-elevation myocardial infarction (STEMI) to reduce LDL\u2011C levels early and effectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this secondary analysis, we included 42\u00a0patients who were na\u00efve to lipid-lowering therapy (LLT) on admission. Aim of the current analysis was to assess individual variations in LDL\u2011C response and to investigate the associations between plasma surrogate markers of cholesterol metabolism at baseline and LDL\u2011C reductions after 4\u20136\u00a0weeks on combined LLT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Combined LLT with atorvastatin 80\u202fmg and ezetimibe 10\u202fmg reduced LDL\u2011C after 6\u00a0weeks in all patients very effectively (47.7\u201392.5%) across all quartiles of cholesterol absorption and synthesis markers. No statistically significant differences in LDL\u2011C reduction were observed across quartiles of cholesterol metabolism markers, although Pearson correlation analysis indicated a\u00a0modest association between sitosterol:cholesterol and LDL\u2011C response. The median LDL\u2011C reduction was &gt;\u202f60% in all quartiles of cholesterol absorption (sitosterol:cholesterol, campesterol:cholesterol, cholestanol:cholesterol) and synthesis markers (lathosterol:cholesterol). We found no statistically significant differences regarding the LDL\u2011C change from baseline (%) in quartiles of sitosterol:cholesterol, campesterol:cholesterol, cholestanol:cholesterol (markers of cholesterol absorption), and lathosterol:cholesterol (marker of cholesterol synthesis). However, Pearson correlation values indicated a\u00a0correlation between sitosterol:cholesterol and LDL\u2011C reduction with higher ratios being associated with less pronounced LDL\u2011C reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Upfront dual therapy with atorvastatin (80\u202fmg) and ezetimibe (10\u202fmg) achieved robust LDL\u2011C reduction with low interindividual variability in treatment-naive individuals. We found no significant association between baseline cholesterol metabolism markers and treatment response. This supports current guideline recommendations for immediate combination therapy in very high-risk patients, irrespective of their baseline metabolic phenotype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00059-026-05393-7","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:52:02Z","timestamp":1788429122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting LDL-cholesterol reduction variability on statin\u2013ezetimibe therapy: insights from \u201cJena auf Ziel\u201d","Vorhersage von Unterschieden in der LDL-Cholesterin-Senkung unter Therapie mit Statin und Ezetimib: Erkenntnisse aus der Studie \u201eJena auf Ziel\u201c"],"prefix":"10.1007","author":[{"given":"Umidakhon","family":"Makhmudova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"L\u00fctjohann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Haertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Kerksiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"R\u00f6mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellumb","family":"Haxhikadrija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurel","family":"Maloku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beasat","family":"Samadifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Christian","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-206X","authenticated-orcid":false,"given":"Oliver","family":"Weing\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"32","key":"5393_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference\u00a0BA et\u00a0al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1.\u00a0Evidence from genetic, epidemiologic, and clinical studies. A\u00a0consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38(32):2459\u20132472","journal-title":"Eur Heart J"},{"issue":"1","key":"5393_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F et\u00a0al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"key":"5393_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.athplu.2021.08.003","volume":"43","author":"KK Ray","year":"2021","unstructured":"Ray\u00a0KK et\u00a0al (2021) Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinational observational SANTORINI study. Atheroscler Plus 43:24\u201330","journal-title":"Atheroscler Plus"},{"issue":"11","key":"5393_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray\u00a0KK et\u00a0al (2021) EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol 28(11):1279\u20131289","journal-title":"Eur J Prev Cardiol"},{"key":"5393_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pharmthera.2019.03.004","volume":"199","author":"D L\u00fctjohann","year":"2019","unstructured":"L\u00fctjohann\u00a0D et\u00a0al (2019) The emerging concept of \u201cindividualized cholesterol-lowering therapy\u201d: A\u00a0change in paradigm. Pharmacol Ther 199:111\u2013116","journal-title":"Pharmacol Ther"},{"issue":"4","key":"5393_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","volume":"21","author":"J Luo","year":"2020","unstructured":"Luo\u00a0J, Yang\u00a0H, Song\u00a0BL (2020) Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol 21(4):225\u2013245","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"5393_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058833","volume":"8","author":"P Singh","year":"2013","unstructured":"Singh\u00a0P et\u00a0al (2013) Cholesterol biosynthesis and homeostasis in regulation of the cell cycle. PLoS One 8(3):e58833","journal-title":"PLoS One"},{"issue":"28","key":"5393_CR8","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1093\/eurheartj\/ehaa445","volume":"41","author":"O Weingartner","year":"2020","unstructured":"Weingartner\u00a0O, Patel\u00a0SB, Lutjohann\u00a0D (2020) It\u2019s time to personalize and optimize lipid-lowering therapy. Eur Heart J 41(28):2629\u20132631","journal-title":"Eur Heart J"},{"issue":"10059","key":"5393_CR9","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins\u00a0R et\u00a0al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388(10059):2532\u20132561","journal-title":"Lancet"},{"issue":"11","key":"5393_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1046\/j.1365-2362.2003.01229.x","volume":"33","author":"TA Miettinen","year":"2003","unstructured":"Miettinen\u00a0TA, Gylling\u00a0H (2003) Synthesis and absorption markers of cholesterol in serum and lipoproteins during a\u00a0large dose of statin treatment. Eur J Clin Invest 33(11):976\u2013982","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"5393_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1067\/mlc.2003.9","volume":"141","author":"TA Miettinen","year":"2003","unstructured":"Miettinen\u00a0TA et\u00a0al (2003) Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J\u00a0Lab Clin Med 141(2):131\u2013137","journal-title":"J Lab Clin Med"},{"issue":"3","key":"5393_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1053\/euhj.2001.3071","volume":"23","author":"GR Thompson","year":"2002","unstructured":"Thompson\u00a0GR, O\u2019Neill\u00a0F, Seed\u00a0M (2002) Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 23(3):200\u2013206","journal-title":"Eur Heart J"},{"issue":"8934","key":"5393_CR13","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383\u20131389","journal-title":"Lancet"},{"issue":"5","key":"5393_CR14","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/01.ATV.20.5.1340","volume":"20","author":"TA Miettinen","year":"2000","unstructured":"Miettinen\u00a0TA, Strandberg\u00a0TE, Gylling\u00a0H (2000) Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 20(5):1340\u20131346","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"29","key":"5393_CR15","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","volume":"38","author":"N Hagiwara","year":"2017","unstructured":"Hagiwara\u00a0N et\u00a0al (2017) Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 38(29):2264\u20132276","journal-title":"Eur Heart J"},{"key":"5393_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2023.06.003","volume":"376","author":"P Simonen","year":"2023","unstructured":"Simonen\u00a0P et\u00a0al (2023) High cholesterol absorption: A\u00a0risk factor of atherosclerotic cardiovascular diseases? Atherosclerosis 376:53\u201362","journal-title":"Atherosclerosis"},{"issue":"2","key":"5393_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.atherosclerosis.2010.01.003","volume":"210","author":"O Weing\u00e4rtner","year":"2010","unstructured":"Weing\u00e4rtner\u00a0O et\u00a0al (2010) Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk. Atherosclerosis 210(2):362\u2013365","journal-title":"Atherosclerosis"},{"issue":"12","key":"5393_CR18","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00392-019-01474-2","volume":"108","author":"O Weing\u00e4rtner","year":"2019","unstructured":"Weing\u00e4rtner\u00a0O et\u00a0al (2019) Low serum lathosterol levels associate with fatal cardiovascular disease and excess all-cause mortality: a prospective cohort study. Clin Res Cardiol 108(12):1381\u20131385","journal-title":"Clin Res Cardiol"},{"issue":"28","key":"5393_CR19","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaa531","volume":"41","author":"A Helgadottir","year":"2020","unstructured":"Helgadottir\u00a0A et\u00a0al (2020) Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease. Eur Heart J 41(28):2618\u20132628","journal-title":"Eur Heart J"},{"key":"5393_CR20","unstructured":"M.G., V., D. M., and B. C.M., Why Combination Lipid-Lowering Therapy Should be Considered Early in the Treatment of Elevated LDL\u2011C For CV Risk Reduction. ACC, 2022."},{"issue":"9","key":"5393_CR21","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s00392-022-02147-3","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova\u00a0U et\u00a0al (2023) Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (\u201cJena auf Ziel\u201d). Clin Res Cardiol 112(9):1212\u20131219","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"5393_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00392-025-02736-y","volume":"115","author":"F Haertel","year":"2026","unstructured":"Haertel\u00a0F et\u00a0al (2026) Less intensive lipid-lowering therapy after ST-elevation myocardial infarction is associated with cardiovascular events: 2\u2011year follow-up of \u201cJena auf Ziel\u201d. Clin Res Cardiol 115(2):304\u2013312","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"5393_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.atherosclerosis.2015.03.004","volume":"240","author":"O Descamps","year":"2015","unstructured":"Descamps\u00a0O et\u00a0al (2015) Variability of the LDL\u2011C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis 240(2):482\u2013489","journal-title":"Atherosclerosis"},{"issue":"4","key":"5393_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","volume":"2","author":"BW Karlson","year":"2016","unstructured":"Karlson\u00a0BW et\u00a0al (2016) Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother 2(4):212\u2013217","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"5393_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jacl.2021.11.013","volume":"16","author":"BA Warden","year":"2022","unstructured":"Warden\u00a0BA et\u00a0al (2022) Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J\u00a0Clin Lipidol 16(1):94\u2013103","journal-title":"J Clin Lipidol"},{"key":"5393_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsbmb.2019.03.009","volume":"190","author":"B \u0160o\u0161i\u0107-Jurjevi\u0107","year":"2019","unstructured":"\u0160o\u0161i\u0107-Jurjevi\u0107\u00a0B et\u00a0al (2019) The isoflavones genistein and daidzein increase hepatic concentration of thyroid hormones and affect cholesterol metabolism in middle-aged male rats. J\u00a0Steroid Biochem Mol Biol 190:1\u201310","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6\/2021","key":"5393_CR27","first-page":"36","volume":"2021","author":"U Makhmudova","year":"2021","unstructured":"Makhmudova\u00a0U et\u00a0al (2021) Kardiovaskul\u00e4re Hochrisikopatienten: Hilfe bei der LDL-C-Zielwerterreichung. CardioVasc 2021(6\/2021):36\u201338","journal-title":"CardioVasc"},{"issue":"4","key":"5393_CR28","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1194\/jlr.P800042-JLR200","volume":"50","author":"TM van Himbergen","year":"2009","unstructured":"van Himbergen\u00a0TM et\u00a0al (2009) Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J\u00a0Lipid Res 50(4):730\u2013739","journal-title":"J Lipid Res"},{"issue":"23","key":"5393_CR29","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren\u00a0MJ et\u00a0al (2014) Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL\u20112 randomized, controlled phase III clinical trial of evolocumab. J\u00a0Am Coll Cardiol 63(23):2531\u20132540","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"5393_CR30","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova\u00a0U et\u00a0al (2023) High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a\u00a0real-world multicenter setting in Germany. Clin Res Cardiol 112(11):1639\u20131649","journal-title":"Clin Res Cardiol"},{"issue":"20","key":"5393_CR31","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal\u00a0F et\u00a0al (2012) Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL\u2011C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126(20):2408\u20132417","journal-title":"Circulation"},{"key":"5393_CR32","doi-asserted-by":"crossref","unstructured":"Zimmermann, F., et\u00a0al., Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids. J\u00a0Clin Med, 2020. 9(5).","DOI":"10.3390\/jcm9051596"},{"issue":"1","key":"5393_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0021-9150(01)00410-5","volume":"158","author":"J Pedro-Botet","year":"2001","unstructured":"Pedro-Botet\u00a0J et\u00a0al (2001) Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158(1):183\u2013193","journal-title":"Atherosclerosis"},{"issue":"1","key":"5393_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.mcna.2011.11.004","volume":"96","author":"HR Superko","year":"2012","unstructured":"Superko\u00a0HR, Momary\u00a0KM, Li\u00a0Y (2012) Statins personalized. Med Clin North Am 96(1):123\u2013139","journal-title":"Med Clin North Am"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-026-05393-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-026-05393-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-026-05393-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:52:04Z","timestamp":1788429124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-026-05393-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":34,"alternative-id":["5393"],"URL":"https:\/\/doi.org\/10.1007\/s00059-026-05393-7","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"U.\u00a0Makhmudova, D.\u00a0L\u00fctjohann, F.\u00a0Haertel, A.\u00a0Kerksiek, R.\u00a0R\u00f6mer, P.\u00a0Haxhikadrija, A.\u00a0Maloku, B.\u00a0Samadifar, S.\u00a0Otto, P.\u00a0C.\u00a0Schulze and O.\u00a0Weing\u00e4rtner declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}